Junbin Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Junbin Liao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Han Xiao
The First Affiliated Hospital of Sun Yat-Sen University Guangzhou China
1 shared publication - Jiehui Tan
Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Man Shu
Department of Pathology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Ming Kuang
Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Qian Zhou
Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication - Ruiming Liang
Department of Medical Statistics, Clinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- 12 July 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (13) , 12365-12377
Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma
Background Liver resection is the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC) while the postoperative prognosis varies greatly, with no recognized biomarker. We aimed to identify the plasma metabolomic biomarkers that could be used for preoperative risk stratification of ICC patients. Methods 108 eligible ICC patients who underwent radical surgical resection between August 2012 and October 2020 were enrolled. Patients were randomly divided into a discovery cohort (n = 76) and a validation cohort (n = 32) by 7:3. Metabolomics profiling of preoperative plasma was performed and clinical data were collected. The least absolute shrinkage and selection operator (LASSO) regression, Cox regression, and receiver operating characteristic (ROC) analyses were used to screen and validate the survival-related metabolic biomarker panel and construct a LASSO-Cox prediction model. Results 10 survival-related metabolic biomarkers were used for construction of a LASSO-Cox prediction model. In the discovery and validation cohorts, the LASSO-Cox prediction model achieved an AUC of 0.876 (95%CI: 0.777–0.974) and 0.860 (95%CI: 0.711–1.000) in evaluating 1-year OS of ICC patients, respectively. The OS of ICC patients in the high-risk group was significantly worse than that in the low-risk group (discovery cohort, p < 0.0001; validation cohort: p = 0.041). Also, the LASSO-Cox risk score (HR 2.43, 95%CI: 1.81–3.26, p < 0.0001) was a significant independent risk factor associated with OS. Conclusions The LASSO-Cox prediction model has potential as an important tool in evaluating the OS of ICC patients after surgical resection and can be used as prediction tools to implement the best treatment options that could result in better outcomes.
- 12 July 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (13) , 12365-12377
Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma
Background Liver resection is the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC) while the postoperative prognosis varies greatly, with no recognized biomarker. We aimed to identify the plasma metabolomic biomarkers that could be used for preoperative risk stratification of ICC patients. Methods 108 eligible ICC patients who underwent radical surgical resection between August 2012 and October 2020 were enrolled. Patients were randomly divided into a discovery cohort (n = 76) and a validation cohort (n = 32) by 7:3. Metabolomics profiling of preoperative plasma was performed and clinical data were collected. The least absolute shrinkage and selection operator (LASSO) regression, Cox regression, and receiver operating characteristic (ROC) analyses were used to screen and validate the survival-related metabolic biomarker panel and construct a LASSO-Cox prediction model. Results 10 survival-related metabolic biomarkers were used for construction of a LASSO-Cox prediction model. In the discovery and validation cohorts, the LASSO-Cox prediction model achieved an AUC of 0.876 (95%CI: 0.777–0.974) and 0.860 (95%CI: 0.711–1.000) in evaluating 1-year OS of ICC patients, respectively. The OS of ICC patients in the high-risk group was significantly worse than that in the low-risk group (discovery cohort, p < 0.0001; validation cohort: p = 0.041). Also, the LASSO-Cox risk score (HR 2.43, 95%CI: 1.81–3.26, p < 0.0001) was a significant independent risk factor associated with OS. Conclusions The LASSO-Cox prediction model has potential as an important tool in evaluating the OS of ICC patients after surgical resection and can be used as prediction tools to implement the best treatment options that could result in better outcomes.